GWW's fourth-quarter 2024 results are likely to reflect gains from upbeat segmental performances and cost-reduction actions.
Vous n'êtes pas connecté
GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma is likely to have been the key driver.
GWW's fourth-quarter 2024 results are likely to reflect gains from upbeat segmental performances and cost-reduction actions.
A robust segmental performance is likely to have benefited RSG's top line in the fourth quarter of 2024.
Robust segmental performances are likely to have driven ECL's performance in the fourth quarter.
SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.
CINF's fourth-quarter results are likely to reflect rate increases, higher policy retention rates and better investment income, offset by higher...
RGA's fourth-quarter results reflect solid performance in the US and Latin America, and Canada segments, offset by a soft performance in Asia/Pacific...
ADM's fourth-quarter results are likely to show mixed performance, with declines in Ag Services & Oilseeds and growth in Nutrition.
Advanced Micro Devices' Q4 2024 results reflect robust Client and Data Center revenues, offsetting weakness in the Gaming and Embedded segments.
The fourth-quarter 2024 results of MAS are likely to reflect mixed contributions from two reportable segments. Dive in to know more about the stock...
West Pharmaceutical Services eyes fourth-quarter growth amid pharma stabilization, biologics rebound & contract manufacturing gains. Can WST sustain...